In recent years, the central role of increased plasma FXI levels, and more generally the role of the activation of the intrinsic pathway, in the development of thrombotic disease, has led pharmaceutical companies to develop numerous molecules with anticoagulant activity that are capable of selectively inhibiting the function of FXI and FXIa [30]. This evidence concerns the gene F11 and thrombotic disease.